Skip to main content
TipRanks
Go Ultimate75% OFF

Drugs Made In America Acquisition Corp. (DMAA) Financial Statements

2 Followers

Drugs Made In America Acquisition Corp. Financial Overview

Drugs Made In America Acquisition Corp.'s market cap is currently $264.62M. The company's EPS TTM is $0.20; its P/E ratio is 55.53; Drugs Made In America Acquisition Corp. has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.

Financial overview
Dec 25Dec 24
Income Statement
Total Revenue$ 0.00$ 0.00
Gross Profit$ 0.00$ 0.00
Operating Income$ -2.82M$ -479.00
EBITDA$ -2.82M$ 479.25K
Net Income$ 5.94M$ -479.00
Balance Sheet
Cash & Short-Term Investments$ 6.14K$ 1.35K
Total Assets$ 239.92M$ 551.00
Total Debt$ 0.00$ 662.00
Net Debt$ -6.14K$ 661.00
Total Liabilities$ 7.28M$ 796.00
Stockholders' Equity$ 232.64M$ -244.00
Cash Flow
Free Cash Flow$ -539.19K$ -295.00
Operating Cash Flow$ -539.19K$ -172.26K
Investing Cash Flow$ -231.15M$ 0.00
Financing Cash Flow$ 231.69M$ 173.62K

Currency in USD

Drugs Made In America Acquisition Corp. Earnings and Revenue History

-4M04M8M0 %0.4 %0.8 %1.2 %EarningsProfit Margin20242025RevenueEarningsProfit Margin

Drugs Made In America Acquisition Corp. Liabilities to Assets

0100M200M300M0 %60 %120 %180 %LiabilitiesLiabilities to Assets20242025AssetsLiabilitiesLiabilities to Assets

Drugs Made In America Acquisition Corp. Cash Flow

-300M-200M-100M0100M200M300M20242025OperatingInvestingFinancing

Drugs Made In America Acquisition Corp. Forecast EPS vs Actual EPS